| 2017-07-31 09:02:18|
AMGN, AGN 09:02 07/31 07/31/17
Amgen and Allergan submit BLA to FDA for ABP 980
Amgen (AMGN) and Allergan (AGN) announced the submission of a Biologics License Application, or BLA, to the FDA for ABP 980, a biosimilar candidate to Herceptin. Amgen and Allergan are collaborating on four oncology biosimilar medicines, including ABP 980 which is the second to be submitted for FDA approval.